| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.36 | 4e-25 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-13 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-12 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-10 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-10 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-09 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-09 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-09 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-09 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-09 |